Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 3.4% – Time to Sell?

by · The Cerbat Gem

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price traded down 3.4% on Thursday . The stock traded as low as $78.99 and last traded at $79.2750. 316,391 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 802,531 shares. The stock had previously closed at $82.07.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. Stifel Nicolaus set a $114.00 target price on Kymera Therapeutics in a research report on Monday, December 8th. Citigroup raised their price target on Kymera Therapeutics from $80.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Oppenheimer lifted their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Finally, Barclays increased their price objective on Kymera Therapeutics from $70.00 to $119.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Buy” and an average price target of $114.45.

Read Our Latest Analysis on Kymera Therapeutics

Kymera Therapeutics Stock Down 4.6%

The company has a market cap of $5.64 billion, a price-to-earnings ratio of -21.77 and a beta of 2.28. The company has a fifty day simple moving average of $66.40 and a two-hundred day simple moving average of $53.16.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The firm had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other news, Director Bruce Booth sold 678 shares of the stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $91.04, for a total value of $61,725.12. Following the sale, the director directly owned 685,393 shares in the company, valued at $62,398,178.72. This represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 488,585 shares of company stock valued at $41,408,199. 16.01% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KYMR. Wellington Management Group LLP raised its stake in Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock valued at $164,134,000 after purchasing an additional 689,547 shares during the last quarter. BVF Inc. IL raised its position in shares of Kymera Therapeutics by 6.6% in the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock valued at $240,138,000 after buying an additional 340,909 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 7.0% during the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock valued at $143,183,000 after buying an additional 344,080 shares during the period. Siren L.L.C. lifted its stake in shares of Kymera Therapeutics by 9.1% during the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after buying an additional 270,580 shares during the period. Finally, Geode Capital Management LLC boosted its position in Kymera Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,193,112 shares of the company’s stock worth $52,075,000 after acquiring an additional 59,347 shares during the last quarter.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Further Reading